4.2 Review

Update on Hemicrania Continua

期刊

CURRENT PAIN AND HEADACHE REPORTS
卷 15, 期 1, 页码 51-56

出版社

SPRINGER
DOI: 10.1007/s11916-010-0156-0

关键词

Chronic daily headache; Indometacin-sensitive headache; Indometacin test; Trigeminal autonomic cephalalgias; International classification of headache disorders

资金

  1. GlaxoSmithKline
  2. MAP Pharmaceuticals, Inc.
  3. Merck, Sharpe, and Dohme
  4. Neuralieve
  5. Boston Scientific

向作者/读者索取更多资源

Hemicrania continua (HC) is a rare primary headache syndrome, characterized by unilateral pain and an absolute response to indometacin. Since the term was first coined in 1984, more than 100 cases have been described worldwide. Most recently, detailed case series that provide more detailed information concerning the sometimes complex clinical presentation of HC have been reported. Functional imaging studies suggest a unique pattern of subcortical involvement in HC: contralateral to the pain posterior hypothalamic region, ipsilateral dorsal pons and ipsilateral ventral midbrain, which, along with the particular effect of indometacin, probably justifies its classification as a unique entity. Increasing the awareness of this primary headache form among clinicians will aid in its diagnosis while further work is being undertaken to characterize the syndrome.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据